Vin .The problem with US life science funds is that they would like Neuren to be listed on the Nasdaq and they would want to put seed money into the market at say $15 mill US and they will support the company .Our problem is that the NASDAQ listing is quiet expensive and the company does not need the money especially after the sale of the ROW.I believe a share buyback is the best option for the company after the sale of the ROW.We probably have just over a month to wait if not sooner !!
Ann: 2018 Year-end Business Update, page-32
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.59 |
Change
0.380(2.50%) |
Mkt cap ! $1.992B | |||
| Open | High | Low | Value | Volume |
| $15.51 | $15.82 | $15.46 | $11.26M | 722.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 696 | $15.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.67 | 6942 | 8 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |